Literature DB >> 15520626

Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.

Emily P Tierney1, Joanna Badger.   

Abstract

CONTEXT: Necrolytic migratory erythema (NME) is a characteristic skin condition seen in the presence of a pancreatic glucagonoma. The presence of NME in the absence of a pancreatic tumor has been termed the pseudoglucagonoma syndrome. In such cases, NME is commonly associated with conditions, such as liver disease, inflammatory bowel disease, pancreatitis, malabsorption disorders (ie, celiac sprue), and other malignancies. There are many theories on the pathogenesis of NME, which include the direct action of glucagon in inducing skin necrolysis, hypoaminoacidemia-inducing epidermal protein deficiency and necrolysis, a nutritional or metabolic deficiency of zinc or essential fatty acids, liver disease, glucagon induction of inflammatory mediators, a substance secreted from pancreatic and other visceral tumors associated with NME, and generalized malabsorption.
OBJECTIVE: To present a review of the literature on the clinical presentation, etiology, pathogenesis, and treatment of NME.
DESIGN: Review of the literature on NME occurring in patients both with and without a pancreatic glucagonoma.
METHODS: We performed a PubMed review of the literature on the etiology and pathogenesis of NME to identify case reports and reviews published in both the internal medicine and dermatology literature.
RESULTS: Our literature review encompassed 17 primary case reports and literature reviews published in the dermatologic and internal medicine literature on NME in patients both with and without a pancreatic glucagonoma. Although we found no clear consensus among the investigators of a universally accepted pathogenesis for NME, we did identify 4 main categories of etiologic/pathogenetic mechanisms for NME (glucagon excess, nutritional deficiencies, inflammatory mediators, and liver disease) that were discussed by many of the investigators and validated by both clinical and scientific evidence.
CONCLUSION: The exact pathogenesis and treatment of NME remain ill-defined despite many case reports and studies on NME in the literature. The many systemic diseases and nutritional deficiencies that have been found to be associated with NME suggest a multifactorial model for the pathogenesis of the disease. The most comprehensive, postulated mechanism for NME involves a combination of zinc, amino acid, and fatty acid deficiencies (arising from a wide variety of causes, such as dietary insufficiency, malabsorption syndromes, liver disease, elevated glucagon levels, and disorders of metabolism) that contributes to increased inflammation in the epidermis in response to trauma and to the necrolysis observed in NME. The importance of gaining an understanding of the etiology and pathogenesis of NME lies in the fact that there is no universally accepted mechanism of pathogenesis for NME, and that the only treatment reported to resolve the rash in these patients is to adequately identify and treat the underlying associated systemic condition or nutritional deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520626      PMCID: PMC1435602     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  15 in total

1.  Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids.

Authors:  S Blackford; S Wright; D L Roberts
Journal:  Br J Dermatol       Date:  1991-11       Impact factor: 9.302

2.  The glucagonoma syndrome. A distinctive cutaneous marker of systemic disease.

Authors:  K H Swenson; R B Amon; J M Hanifin
Journal:  Arch Dermatol       Date:  1978-02

3.  A glucagon-secreting alpha-cell carcinoma of the pancreas.

Authors:  M H McGavran; R H Unger; L Recant; H C Polk; C Kilo; M E Levin
Journal:  N Engl J Med       Date:  1966-06-23       Impact factor: 91.245

Review 4.  The glucagonoma syndrome: clinical features, diagnosis, and treatment.

Authors:  P W Stacpoole
Journal:  Endocr Rev       Date:  1981       Impact factor: 19.871

Review 5.  Necrolytic migratory erythema: unresolved problems in diagnosis and pathogenesis. A case report and literature review.

Authors:  C S Kasper
Journal:  Cutis       Date:  1992-02

6.  Necrolytic migratory erythema without glucagonoma.

Authors:  D M Goodenberger; T J Lawley; W Strober; L Wyatt; M H Sangree; R Sherwin; H Rosenbaum; I Braverman; S I Katz
Journal:  Arch Dermatol       Date:  1979-12

7.  Clinical and metabolic aspects of glucagonoma.

Authors:  S B Leichter
Journal:  Medicine (Baltimore)       Date:  1980-03       Impact factor: 1.889

8.  Glucagonoma syndrome: in vitro evidence that glucagon increases epidermal arachidonic acid.

Authors:  L L Peterson; J C Shaw; K M Acott; P A Mueggler; F Parker
Journal:  J Am Acad Dermatol       Date:  1984-09       Impact factor: 11.527

9.  Effects of albumin on fatty acid, protein, and eicosanoid levels in rat mesenteric arterial bed perfusions.

Authors:  D K Jenkins; J C Mitchell; M S Manku; D F Horrobin
Journal:  Can J Physiol Pharmacol       Date:  1988-06       Impact factor: 2.273

10.  Acrodermatitis enteropathica, zinc metabolism, copper status, and immune function.

Authors:  B Sandström; A Cederblad; B S Lindblad; B Lönnerdal
Journal:  Arch Pediatr Adolesc Med       Date:  1994-09
View more
  13 in total

1.  Necrolytic migratory erythema.

Authors:  Hyun Ji Lee; Yong Hyun Jang
Journal:  CMAJ       Date:  2019-03-11       Impact factor: 8.262

2.  Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Authors:  Cristina Saavedra; Angela Lamarca; Richard A Hubner
Journal:  BMJ Case Rep       Date:  2019-08-10

3.  [Migratory necrolytic erythema as a manifestation of pancreatic neuroendocrine tumor. Clinical-radiological evaluation].

Authors:  Gonzalo Dulcich; Marcos Alejandro Mestas Nuñez; Ernestina Maria Jose Gentile
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2022-06-06

4.  Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Authors:  Stephanie A C Halvorson; Erin Gilbert; R Samuel Hopkins; Helen Liu; Charles Lopez; Michael Chu; Marie Martin; Brett Sheppard
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

5.  [Psoriasiform exanthem in a patient with MEN-I].

Authors:  A Maronna; G Schuler; H Schell; M Simon
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

6.  A Glucagonoma Presenting as Cerebral Vein Thrombosis and Diabetes.

Authors:  Marina Delli Colli; Bader N Alamri; Laura Palma; Juan Rivera
Journal:  Case Rep Endocrinol       Date:  2022-04-22

7.  Glucagonoma syndrome: a case report with focus on skin disorders.

Authors:  Sheng Fang; Shuang Li; Tao Cai
Journal:  Onco Targets Ther       Date:  2014-08-14       Impact factor: 4.147

Review 8.  Zinc and Skin Disorders.

Authors:  Youichi Ogawa; Manao Kinoshita; Shinji Shimada; Tatsuyoshi Kawamura
Journal:  Nutrients       Date:  2018-02-11       Impact factor: 5.717

9.  Glucagonoma syndrome with serous oligocystic adenoma: A rare case report.

Authors:  Yun Gao; Chun Wang; Yunyi Gao; Huijiao Chen; Bing Peng; Weixia Chen; Xingwu Ran
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

10.  Clinical features and amino acid profiles of dogs with hepatocutaneous syndrome or hepatocutaneous-associated hepatopathy.

Authors:  John P Loftus; Sharon A Center; Michael Astor; Adam J Miller; Jeanine Peters-Kennedy
Journal:  J Vet Intern Med       Date:  2021-09-02       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.